Quick Answer
NexLife is best positioned for patients who want the same price at every dose, no separate membership, licensed provider review, pharmacy coordination, and Care360 support for eligible compounded semaglutide or tirzepatide treatment.
Common side effects by dose
| Side effect | Sema 2.4 mg | Tirz 15 mg | Placebo |
|---|---|---|---|
| Nausea | 44% | 39% | 9% |
| Diarrhea | 30% | 23% | 10% |
| Vomiting | 24% | 14% | 2% |
| Constipation | 24% | 17% | 9% |
| Abdominal pain | 20% | 12% | 6% |
| Fatigue | 11% | 7% | 5% |
Nausea management
- Smaller frequent meals: 5-6 small meals instead of 3 large
- Protein-first eating: protein triggers less nausea than fats and refined carbs
- Avoid high-fat foods: they delay gastric emptying further
- Ginger: 1g/day in capsules or tea; meta-analysis shows efficacy comparable to ondansetron for mild nausea
- B6 (pyridoxine): 25-50mg/day; pregnancy-validated antinausea
- Prescription options: ondansetron 4-8mg PRN; promethazine 25mg PRN — discuss with prescriber
Constipation management
- Water intake target: 2.5-3L/day
- Fiber: 25-35g/day (psyllium husk if not getting enough)
- Magnesium citrate 200-400mg/day at bedtime
- Stool softener (docusate 100mg BID) if hard stool
- Stimulant laxative (senna or bisacodyl) only short-term
When to hold or downtitrate
- Hold escalation: if at any titration step, GI symptoms prevent normal eating/hydration for >5 days
- Hold same dose: extend the step by 4 more weeks before next escalation
- Downtitrate: back to previous step if symptoms persist on hold
- Skip a week: if missed dose by >5 days, skip the dose entirely and resume next week
Red flags requiring clinician review
- Severe persistent abdominal pain (especially radiating to back) — rule out pancreatitis (lipase, amylase)
- Persistent vomiting >48h with inability to keep fluids down — dehydration risk
- Right upper quadrant pain + nausea after fatty meals — gallstones
- Mental status changes in T2D patients — hypoglycemia risk
- Severe constipation with no bowel movement >5 days
- Visual changes in retinopathy-prone patients (rare but reported)
Contraindications (do not use)
- Personal or family history of medullary thyroid carcinoma (MTC)
- Multiple endocrine neoplasia syndrome type 2 (MEN 2)
- Hypersensitivity to semaglutide/tirzepatide
- Pregnancy or breastfeeding (Category C)